Minimizing the environmental impact of our operations is essential to promoting healthy communities that thrive on a clean and sustainable planet.
The primary environmental focus areas for Catalent are:
- “CO₂ emissions linked to energy use at manufacturing sites
- Hazardous and non-hazardous waste generation
- Water use and water quality, particularly as it relates to the presence of Active Pharmaceutical Ingredients (API)
Catalent is committed to reducing its environmental footprint. We track our progress toward four goals (normalized per million dollars of revenue).
Our Standards of Business Conduct commit Catalent to minimize our impact on the environment, complying with relevant laws, and operating with the required environmental permits, approvals, and controls.
Our management systems help us continuously improve our performance by investing in better, cleaner, and more efficient ways of running our operations. The British Standards Institute (BSI Group) recently awarded Catalent a Global accreditation against the international management standards for environment (ISO14001:2015) and occupational safety (OHSAS18001:2007)
REDUCING ENERGY USE AND EMISSIONS
Most of our energy consumption, waste generation, and water use take place at our global manufacturing sites. We are actively implementing programs and projects to reduce the environmental impact of these sites.
Our sites report environmental data through an internal sustainability scorecard. The baseline year for our current environmental reduction plan is FY17. The data guides our environmental strategy and helps our sites improve operational best practices and minimize our footprint on the planet.
CO₂ emissions linked to energy use in operations make up the largest portion of our operational carbon footprint.
The FY17 – FY19 energy data represents the footprint of 30 Catalent manufacturing sites. Historical data is not currently available for 3 manufacturing sites but will be included as data collection improves.
This graph represents the total CO₂ emissions (linked to energy use) of 30 Catalent manufacturing sites for FY17 – FY19. Historical data is not currently available for three manufacturing sites but will be included as data collection improves.
RESPONSIBLY MANAGING OUR WASTE
We continually assess our waste profile, particularly as it relates to API in wastewater. Following the most recent review, we have identified the key sites in our network to invest in additional treatment options, including UV-Sequestration, which renders API molecules to less harmful material.
As another example, waste from our Softgel manufacturing operations (gel-net) is often sold and recycled to make adhesive products.
ENVIRONMENTAL IMPACT OF OUR SUPPLY CHAIN
We are active members of the Pharmaceutical Supply Chain Initiative (PSCI), a group of companies from the healthcare and pharmaceutical sector dedicated to minimizing the industry’s environmental impacts. Since joining the initiative in 2016, we have collaborated with suppliers, customers, and competitors to drive responsible supply chain management and better business across the pharmaceutical sector.
For more information on Corporate Responsibility & Sustainability at Catalent, email us or follow #catalentcares on social media.